A “cookie cutter” technique for COVID drug discovery

“Beyond COVID-19, we believe SMAs have huge potential to unblock constrictions in the drug pipeline.”
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

BIRMINGHAM, UK—University of Birmingham researchers are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future antiviral drugs.

The encounter complex is formed when the COVID-19 spike latches onto a binding site on an ACE-2 receptor, which is a complex protein embedded in cell membranes in the lungs, as well as cells that line the nose and airways.

Although it was first isolated last year, the methods used involved full extraction of ACE-2 receptors from cell membranes, and this removal of the membrane’s supportive structure affects the stability of the receptor, which makes it difficult to study its structure and function.

The Birmingham researchers are using polymer-based molecular “cookie cutters” to isolate the complex and keep it embedded in the cell membrane, thus preserving the full structure of the molecule in its original context and in a stable form. The polymers are called styrene maleic anhydrides, or SMAs, and the resulting structure is known as an SMA lipid particle, or SMALP, as it includes lipids from the cell membranes.

The technique was invented by Tim Dafforn from the University’s School of Biosciences, who led researchers at the Universities of Birmingham and Oxford to extract what they believe is the first ever COVID-19 encounter complex with an intact membrane.

This initial project, which was funded by UKRI/BBSRC COVID-19 Rapid Response funding, also includes characterizing the complex with a view to publishing its structure. The researchers have also received funding from Innovate UK that will enable a wider team to determine which area of the complex will be the most effective for anti-viral drug discovery efforts.

The SMAs used in the study were provided by Netherlands-based company Orbiscope, which is a business unit of Polyscope Polymers B.V., and the world’s largest producer or SMAs for high-end applications including laminates for printed circuit boards, architectural and printed coatings, paints, performance materials used in cars, and cosmetics. 

Said Bart Verbraeken, business unit manager at Orbiscope: “Beyond COVID-19, we believe SMAs have huge potential to unblock constrictions in the drug pipeline, by enabling studies of receptors in their native environments that will define drug targets more precisely than ever before.”

Related Topics

Published In

Volume 17 - Issue 5 | May 2021

May 2021

May 2021 issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue